InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.430

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$206 Response to ASX Query re Share Price 28 Sep 2005 9:14AM $0.585 $0.430 fallen by 26.50%
$206 Preliminary Final Report & Commentary 6 Sep 2005 2:03PM $0.470 $0.430 fallen by 8.51%
$206 Commitments Test Entity - Fourth Quarter Report 28 Jul 2005 4:12PM $0.535 $0.430 fallen by 19.63%
$206 Starpharma investee company DNT-new low cost nanostructures 19 May 2005 11:02AM $0.550 $0.430 fallen by 21.82%
$206 Investee Company Dimerix Bioscience offered Grant 11 May 2005 3:05PM $0.590 $0.430 fallen by 27.12%
$206 To receive up to $5.6m grant for product development 1 Apr 2005 9:56AM $0.690 $0.430 fallen by 37.68%
$206 Work with Anadis on Respiratory Protection/Biodefense App. 1 Feb 2005 10:09AM $0.870 $0.430 fallen by 50.57%
$206 Reinstatement to Official Quotation 27 Jan 2005 9:11AM $0.870 $0.430 fallen by 50.57%
$206 Suspension from Official Quotation 24 Jan 2005 9:46AM n/a $0.430 n/a
$206 Trading Halt 20 Jan 2005 9:44AM n/a $0.430 n/a
$206 Clinical study shows VivaGel is safe 16 Dec 2004 9:16AM $0.790 $0.430 fallen by 45.57%
$206 Reports positive clinical results for VivaGel 17 Nov 2004 7:33PM $0.740 $0.430 fallen by 41.89%
$206 Starpharma to lead US$5.4M NIH project for HIV prevention 30 Sep 2004 3:05PM $0.880 $0.430 fallen by 51.14%
$206 VivaGel FDA Clearance for 3rd Stage dosing in Phase 1 trial 3 Aug 2004 10:30AM $0.870 $0.430 fallen by 50.57%
$206 Granted Additional Nanotechnology Patent in USA 7 Jun 2004 2:04PM $0.760 $0.430 fallen by 43.42%
$206 Phase 1 Clinical Study - advancing to second stage 27 Apr 2004 10:20AM $0.740 $0.430 fallen by 41.89%
$206 Phase 1 Clinical Study - advancing to second stage 27 Apr 2004 10:20AM $0.740 $0.430 fallen by 41.89%
$206 Institutional share placement 18 Mar 2004 9:27AM $0.930 $0.430 fallen by 53.76%
$206 Trading Halt 17 Mar 2004 9:15AM n/a $0.430 n/a
$206 Half Yearly Report & Half Year Accounts 25 Feb 2004 9:42AM $0.870 $0.430 fallen by 50.57%
$206 DNT Inc - New Patents granted/Recieves add grant funding 18 Nov 2003 3:46PM $0.590 $0.430 fallen by 27.12%
$206 US award for Starpharma Associate DNT Inc 8 Oct 2003 12:31PM $0.630 $0.430 fallen by 31.75%
$206 Preliminary Final Report 11 Sep 2003 2:23PM $0.630 $0.430 fallen by 31.75%
$206 Placement 10 Sep 2003 9:39AM $0.600 $0.430 fallen by 28.33%
$206 Trading Halt 8 Sep 2003 9:39AM n/a $0.430 n/a

876 - 900 of 901 results

Page 36 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.